来那卡帕韦联合两种广谱中和抗体治疗HIV-1低水平病毒学反弹的耐药分析
本研究为1b期试验的耐药分析,纳入30例病毒学抑制的HIV-1感染者,接受来那卡帕韦联合特罗帕韦单抗和津利韦单抗治疗。至第26周,1/30例出现病毒学失败并检出衣壳Q67H突变(来那卡帕韦倍数变化4.7),无bNAb耐药;2例 pilot 队列出现低水平病毒学反弹,未出现来那卡帕韦耐药或bNAb敏感性改变。结论支持该联合方案进一步开展2期评估。
要点
- 来那卡帕韦联合bNAb在26周内维持高病毒学抑制率,耐药罕见。
- 1例病毒学失败者检出衣壳Q67H突变,来那卡帕韦倍数变化4.7,无bNAb耐药。
- 2例低水平病毒学反弹者未出现来那卡帕韦耐药或bNAb敏感性改变。
核心结论
- 来那卡帕韦联合特罗帕韦单抗和津利韦单抗至第26周维持高病毒学抑制率,来那卡帕韦耐药罕见且无bNAb耐药,支持进一步2期评估。
研究设计与样本
- 1b期研究(NCT04811040)的耐药分析,纳入病毒学抑制且对两种bNAb均敏感(IC90 ≤ 2 μg/mL)的原发队列20例或对任一bNAb敏感的pilot队列10例,共30例。
主要发现
- 30例中1例(原发队列)出现病毒学失败,第16周HIV RNA 155 copies/mL,检出衣壳Q67H突变(来那卡帕韦倍数变化4.7),无bNAb耐药,恢复口服抗逆转录病毒后重新抑制。
- pilot队列2例在第26周出现病毒学反弹(55和72 copies/mL),重启口服抗逆转录病毒;探索性分析未发现来那卡帕韦耐药或bNAb敏感性改变。
临床怎么用
- 该联合方案在病毒学抑制且对bNAb敏感的HIV-1感染者中显示高抑制率,但需监测病毒学反弹及衣壳突变(如Q67H)。
- 出现病毒学失败或反弹时,应进行耐药检测并考虑恢复口服抗逆转录病毒治疗。
局限性
- 样本量小(原发队列20例,pilot队列10例),随访至第26周,耐药分析为探索性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: High rates of virologic suppression were observed in the Phase 1b study (NCT04811040) investigating lenacapavir and two broadly neutralizing antibodies (bNAb), teropavimab (30 mg/kg) and zinlirvimab (10 or 30 mg/kg), in virologically suppressed people with HIV-1 susceptible (IC90 ≤ 2 μg/mL) to both (primary cohort, n = 20) or either (pilot cohort, n = 10) bNAb. We describe resistance analyses through Week (W) 26. METHODS: Post-baseline resistance analyses were conducted at virologic failure, and exploratory resistance analyses performed for participants with virologic rebound. Low copy number genotyping methods for capsid and a 1 kb stretch of gp120 from rebound virus were developed, and phenotypic susceptibility assessed. RESULTS: Virologic failure was observed in 1/30 participants. This primary cohort participant had HIV RNA 155 copies/mL at W16 and developed Q67H in capsid (lenacapavir fold-change 4.7), without resistance to bNAbs; the participant resuppressed on oral antiretrovirals. Two pilot cohort participants, experienced virologic rebound at W26 (55 and 72 copies/mL) and restarted oral antiretrovirals. In exploratory analyses, neither had emergent lenacapavir resistance or altered bNAb susceptibility. CONCLUSIONS: Lenacapavir, teropavimab, and zinlirvimab maintained a high rate of virologic suppression through W26, with rare emergent lenacapavir resistance and no bNAb resistance, supporting further Phase 2 evaluation.
引用
- Selzer L, Demirdjian S, Falkard B, et al. Resistance Analysis of Low-Level Virologic Rebound During HIV-1 Treatment With Lenacapavir and Broadly Neutralizing Antibodies Teropavimab and Zinlirvimab. J Infect Dis. 2026. PMID: 41205622. doi:10.1093/infdis/jiaf559
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。